Humana Inc. has reaffirmed its full-year fiscal 2026 adjusted earnings per share (EPS) guidance of at least $9.

The US health insurer maintained this target in its latest filing with the Securities and Exchange Commission, indicating no change to its previously stated financial expectations for the current fiscal year.

Guidance Stability

The company’s decision to keep the adjusted EPS floor at $9 suggests management remains confident in its operational trajectory and cost management strategies for the remainder of FY26. This figure serves as a key benchmark for investors assessing Humana’s profitability outlook amid evolving healthcare dynamics.

What the Numbers Show

The reaffirmation of the $9 EPS target implies that Humana expects its revenue growth and margin performance to align with prior estimates. Without downward revision, the company signals that no material headwinds have emerged to disrupt its annual profit path.

Humana Inc. (NYSE: HUM) appointed Dr. Shantanu Nundy as Chief Medical Officer, effective August 31. The appointment positions a physician with deep expertise in technology-driven care to shape the company’s clinical strategy, product design, and artificial intelligence initiatives. Dr. Nundy will report directly to Jim Rechtin, Humana President and CEO, and serve as a member of the Enterprise Leadership Team.

Strategic Focus on Clinical Technology

Dr. Nundy’s role centers on merging clinical excellence with technological innovation. He will help design Humana’s products and platforms, leveraging his background in using technology to simplify care pathways. The company stated that his experience at the intersection of clinical outcomes, technology, and consumer experience is intended to advance efforts to simplify the path to care.

Jim Rechtin highlighted the strategic importance of the hire, noting that clinical excellence is central to Humana’s vision of becoming a leading consumer healthcare company. The leadership team expects Dr. Nundy’s insights to help members achieve better health outcomes through more accessible and human-centric service models.

Professional Background

Dr. Nundy brings extensive experience in healthcare navigation and digital transformation. His recent roles include:

• Accolade: Served as Executive Vice President of Care Delivery and Chief Health Officer, leading a technology-driven transformation of member care experiences.
• Evolent Health: Acted as Managing Director for Clinical Innovation, driving value-based and digital care changes across large health systems.

Beyond corporate roles, Dr. Nundy remains an active clinician, practicing primary care at a community health center and hospital medicine at a regional health system. He has advised organizations including the U.S. Food and Drug Administration and the World Bank on digital health and AI. He also serves on the adjunct faculty at Stanford Medicine and Johns Hopkins Carey Business School.

Educational Credentials

Dr. Nundy holds degrees from three major institutions:

He is also the author of two books on healthcare topics.